• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

BK060008 Letter

May 23, 2006

Haemonetics Corporation
Attn: Susan Finneran
400 Wood Road
Braintree, MA 02184


Re: BK060008
Product: Haemonetics ACP 215 Glycerolization/Deglycerolization System
Date Received: 02-FEB-06
Classification: II
Device Code: KSW

Dear Ms. Finneran:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device has been classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice on promotional labeling and advertisement for your device, please contact our Advertising and Promotional Labeling Staff (HFM-602) at (301) 827-3028. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 835-4709 or (301) 827-1800 or at its Internet address: http://www.fda.gov/cber/smlbus.htm.

Sincerely yours,

Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics Evaluation and Research



Indications for Use

510(k) Number: BK060008

Device Name: Haemonetics ACP 215 System

Indications For Use:

The ACP 215 is intended to glycerolize and deglycerolize red blood cells derived from whole blood that have been stored in any approved anticoagulant/additive solution for up to 6 days at 1-6°C prior to glycerolization.

Red blood cells, derived from whole blood collections and non-leukoreduced, that have been collected and stored in CPDA-1, using the ACP 215 and frozen at -65°C or colder and deglycerolized using the ACP 215 and stored in Haemonetics AS-3 at 1-6°C may be labeled for extended storage for 14 days.

Red blood cells that have been collected and stored in CPD/AS-1, or CPD/AS-3 (leukoreduced) or CPD/AS-5 (Leukoreduced or non-leukoreduced) glycerolized using the ACP 215, frozen at -65°C or colder, deglycerolized by the ACP 215, and stored in Haemonetics AS-3 at 1-6°C may be labeled for extended storage for 14 days. Whole blood derived red blood cells collected in any other anticoagulant/additive solution will be labeled with a 24- hour outdate.

Red cells, non-leukoreduced, that were manually glycerolized using the 40% W/V Glycerol (Valeri Method) and frozen at -65°C or colder may be deglycerolized using the ACP 215 and labeled with a 24 hour outdate.